Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease

Life Sciences

Volumn 136, Issue , 2015, Pages 108-119

  Salkovic Petrisic, Melita ^a   Knezovic, Ana ^a   Osmanovic Barilar, Jelena ^a   Smailovic, Una ^a   Trkulja, Vladimir ^a   Riederer, Peter ^b   Amit, Tamar ^c   Mandel, Silvia ^c   Youdim, Moussa B H ^c  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Alzheimer's disease; HLA20 compound; Insulin degrading enzyme; M30 compound; Memory; Streptozotocin; Tau protein

Indexed keywords

IRON CHELATING AGENT; STREPTOZOCIN; UNCLASSIFIED DRUG; [5 (4 PROPARGYLPIPERAZIN 1 YLMETHYL) 8 HYDROXYQUINOLINE]; [[5 (N METHYL N PROPARGYLAMINOMETHYL) 8 HYDROXYQUINOLINE]]; 5-((4-PROP-2-YNYLPIPERAZIN-1-YL)METHYL)QUINOLIN-8-OL; NEUROPROTECTIVE AGENT; PIPERAZINE DERIVATIVE; QUINOLINOL DERIVATIVE;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IN VIVO STUDY; IRON CHELATION; LONG TERM CARE; LONG TERM MEMORY; MALE; MORRIS WATER MAZE TEST; NONHUMAN; PASSIVE AVOIDANCE; RAT; REFERENCE MEMORY; SPATIAL LEARNING; SPATIAL MEMORY; SPORADIC ALZHEIMERS DISEASE; SWIMMING; TREATMENT DURATION; WORKING MEMORY; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; MEMORY DISORDERS; PSYCHOLOGY; WISTAR RAT;

ANIMALIA; RATTUS;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HYDROXYQUINOLINES; IRON CHELATING AGENTS; MALE; MEMORY DISORDERS; MEMORY, LONG-TERM; NEUROPROTECTIVE AGENTS; PIPERAZINES; RATS, WISTAR; STREPTOZOCIN;

EID: 84937431034     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2015.06.026     Document Type: Article

References (59)

1. P.A. Adlard, L. Bica, A.R. White, M. Nurjono, G. Filiz, P.J. Crouch, P.S. Donnelly, R. Cappai, D.I. Finkelstein, and A.I. Bush Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease PLoS One 6 2011 e17669 10.1371/journal.pone.0017669
2. R. Agrawal, E. Tyagi, R. Shukla, and C. Nath Insulin receptor signaling in rat hippocampus: a study in STZ (ICV) induced memory deficit model Eur. Neuropsychopharmacol. 21 2011 261 273
3. C. Balducci, and G. Forloni APP transgenic mice: their use and limitations Neuromolecular Med. 13 2011 117 137
4. D. Ben-Shachar, N. Kahana, V. Kampel, A. Warshawsky, and M.B. Youdim Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats Neuropharmacology 46 2004 254 263
5. A. Blokland, and J. Jolles Spatial learning deficit and reduced hippocampal ChAT activity in rats after an ICV injection of streptozotocin Pharmacol. Biochem. Behav. 44 1993 491 494
6. B. Borroni, M. Grassi, C. Costanzi, S. Archetti, L. Caimi, and A. Padovani APOE genotype and cholesterol levels in Lewy body dementia and Alzheimer disease: investigating genotype-phenotype effect on disease risk Am. J. Geriatr. Psychiatr. 14 2006 1022 1031
7. A. Budimir Metal ions, Alzheimer's disease and chelation therapy Acta Pharma. 61 2011 1 14
8. R.A. Cherny, C.S. Atwood, M.E. Xilinas, D.N. Gray, W.D. Jones, C.A. McLean, K.J. Barnham, I. Volitakis, F.E. Fraser, Y. Kim, X. Huang, L.E. Goldstein, R.D. Moir, J.T. Lim, K. Beyreuther, H. Zheng, R.E. Tanzi, C.L. Masters, and A.I. Bush Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice Neuron 30 2001 665 676
9. S.C. Correia, R.X. Santos, G. Perry, X. Zhu, P.I. Moreira, and M.A. Smith Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res. Rev. 10 2011 264 273
10. D.R. Crapper McLachlan, A.J. Dalton, T.P. Kruck, M.Y. Bell, W.L. Smith, W. Kalow, and D.F. Andrews Intramuscular desferrioxamine in patients with Alzheimer's disease Lancet 337 1991 1304 1308
11. R.R. Crichton, D.T. Dexter, and R.J. Ward Brain iron metabolism and its perturbation in neurological diseases J. Neural Transm. 118 2011 301 314
12. S.M. de la Monte, and J.R. Wands Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease J. Alzheimers Dis. 7 2005 45 61
13. Y. Deng, B. Li, Y. Liu, K. Iqbal, I. Grundke-Iqbal, and C.X. Gong Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer's disease Am. J. Pathol. 175 2009 2089 2098
14. L. Frölich, D. Blum-Degen, H.G. Bernstein, S. Engelsberger, J. Humrich, S. Laufer, D. Muschner, A. Thalheimer, A. Turk, S. Hoyer, R. Zochling, K.W. Boissl, K. Jellinger, and P. Riederer Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease J. Neural Transm. 105 1998 423 438
15. E. Grünblatt, J. Bartl, and P. Riederer The link between iron, metabolic syndrome and Alzheimer's disease J. Neural Transm. 118 2010 371 379
16. E. Grünblatt, M. Salkovic-Petrisic, J. Osmanovic, P. Riederer, and S. Hoyer Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein J. Neurochem. 101 2007 757 770
17. C. Guo, P. Wang, M.L. Zhong, T. Wang, X.S. Huanq, J.Y. Li, and Z.Y. Wang Deferoxamine inhibits iron-induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain Neurochem. Int. 62 2013 165 172
18. C. Guo, T. Wang, W. Zheng, Z.Y. Shan, W.P. Teng, and Z.Y. Wang Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease Neurobiol. Aging 34 2013 562 575
19. R. Hellweg, R. Nitsch, C. Hock, M. Jaksch, and S. Hoyer Nerve growth factor and choline acetyltransferase activity levels in the rat brain following experimental impairment of cerebral glucose and energy metabolism J. Neurosci. Res. 31 1992 479 486
20. K. Honda, G. Casadesus, R.B. Petersen, G. Perry, and M.A. Smith Oxidative stress and redox-active iron in Alzheimer's disease Ann. N. Y. Acad. Sci. 1012 2004 179 182
21. C. Kilkenny, W. Browne, I.C. Cuthill, M. Emerson, and D.G. Altman Animal research: reporting in vivo experiments: the ARRIVE guidelines Br. J. Pharmacol. 160 2010 1577 1579
22. A. Knezovic, J. Osmanovic-Barilar, M. Curlin, P.R. Hof, G. Simic, P. Riederer, and M. Salkovic-Petrisic Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease J. Neural Transm. 122 2015 577 592
23. L. Kupershmidt, T. Amit, O. Bar-Am, M.B. Youdim, and O. Weinreb The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease Antioxid. Redox Signal. 17 2012 860 877
24. H. Lannert, and S. Hoyer Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats Behav. Neurosci. 112 1998 1199 1208
25. Y. Lee, Y.H. Kim, S.J. Park, J.W. Huh, S.H. Kim, S.U. Kim, J.S. Kim, K.J. Jeong, K.M. Lee, Y. Hong, S.R. Lee, and K.T. Chang Insulin/IGF signaling-related gene expression in the brain of a sporadic Alzheimer's disease monkey model induced by intracerebroventricular injection of streptozotocin J. Alzheimers Dis. 38 2014 251 267
26. N. Lester-Coll, E.J. Rivera, S.J. Soscia, K. Doiron, J.R. Wands, and S. de la Monte Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease J. Alzheimers Dis. 9 2006 13 33
27. C.U. Lithner, M.M. Hedberg, and A. Nordberg Transgenic mice as a model for Alzheimer's disease Curr. Alzheimer Res. 8 2011 818 831
28. P. Liu, L.B. Zou, L.H. Wang, Q. Jiao, T.Y. Chi, X.F. Ji, and G. Jin Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats Psychopharmacology 231 2014 345 356
29. F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci, and M. Kivipelto Alzheimer's disease: clinical trials and drug development Lancet Neurol. 9 2010 702 716
30. G. Mayer, R. Nitsch, and S. Hoyer Effects of changes in peripheral and cerebral glucose metabolism on locomotor activity, learning and memory in adult male rats Brain Res. 532 1990 95 100
31. S. McMahon, F. Grondin, P.P. McDonald, D.E. Richard, and C.M. Dubois Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins J. Biol. Chem. 280 2005 6561 6569
32. D. Mechlovich, T. Amit, S.A. Mandel, O. Bar-Am, K. Bloch, P. Vardi, and M.B. Youdim The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage J. Pharmacol. Exp. Ther. 333 2010 874 882
33. D. Mechlovich, T. Amit, O. Bar-Am, S. Mandel, M.B. Youdim, and O. Weinreb The novel multi-target iron chelator, M30 modulates HIF-1α-related glycolytic genes and insulin signaling pathway in the frontal cortex of APP/PS1 Alzheimer's disease mice Curr. Alzheimer Res. 11 2014 119 127
34. D. Mechlovich, T. Amit, O. Bar-Am, O. Wienreb, and M.B. Youdim Brain molecular targets of the multifunctional iron chelating drug, M30 in type 2 diabetes mellitus mouse models Br. J. Pharmacol. 2014 10.1111/bph.12862 [Epub ahead of print]
35. A.M. Morris, J.C. Churchwell, R.P. Kesner, and P.E. Gilbert Selective lesions of the dentate gyrus produce disruptions in place learning for adjacent spatial locations Neurobiol. Learn. Mem. 97 2012 326 331
36. J. Osmanovic Barilar, A. Knezovic, E. Grünblatt, P. Riederer, and M. Salkovic-Petrisic Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer's disease J. Neural Transm. 122 2015 565 576
37. D. Peng, X. Pan, J. Cui, Y. Ren, and J. Zhang Hyperphosphorylation of tau protein in hippocampus of central insulin-resistant rats is associated with cognitive impairment Cell. Physiol. Biochem. 32 2013 1417 1425
38. K. Plaschke, and S. Hoyer Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus Int. J. Dev. Neurosci. 11 1993 477 483
39. C.W. Ritchie, A.I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q.X. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis, M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R.E. Tanzi, and C.L. Masters Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial Arch. Neurol. 60 2003 1685 1691
40. M. Salkovic-Petrisic, A. Knezovic, S. Hoyer, and P. Riederer What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research J. Neural Transm. 120 2012 233 252
41. M. Salkovic-Petrisic, J. Osmanovic-Barilar, M.K. Brückner, S. Hoyer, T. Arendt, and P. Riederer Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study J. Neural Transm. 118 2011 765 772
42. M. Salkovic-Petrisic, F. Tribl, M. Schmidt, S. Hoyer, and P. Riederer Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway J. Neurochem. 96 2006 1005 1015
43. S. Salomone, F. Caraci, G.M. Leggio, J. Fedotova, and F. Drago New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Br. J. Clin. Pharmacol. 73 2012 504 517
44. T.D. Santos, C.H. Mazucanti, G.F. Xavier, and A.D. Torrão Early and late neurodegeneration and memory disruption after intracerebroventricular streptozotocin Physiol. Behav. 107 2012 401 413
45. G. Saxena, I.K. Patro, and C. Nath ICV STZ induced impairment in memory and neuronal mitochondrial function: a protective role of nicotinic receptor Behav. Brain Res. 224 2011 50 57
46. M. Sharma, and Y.K. Gupta Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment Life Sci. 68 2001 1021 1029
47. H. Shinall, E.S. Song, and L.B. Hersh Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral Biochemistry 44 2005 15345 15350
48. A.S. Shingo, T. Kanabayashi, S. Kito, and T. Murase Intracerebroventricular administration of an insulin analogue recovers STZ-induced cognitive decline in rats Behav. Brain Res. 241 2013 105 111
49. L. Silvestri, and C. Camaschella A potential pathogenetic role of iron in Alzheimer's disease J. Cell. Mol. Med. 12 2008 1548 1550
50. T. Szkudelski The mechanism of alloxan and streptozotocin action in B cell of the rat pancreas Physiol. Res. 50 2001 537 546
51. E. Sofic, M. Salkovic-Petrisic, I. Tahirovic, A. Sapcanin, S. Mandel, P. Youdim, and P. Riederer Brain catalase in the streptozotocin-rat model of sporadic Alzheimer's disease treated with the iron chelator-monoamine oxidase inhibitor, M30 J. Neural Transm. 2014 2014 Sep 25 [Epub ahead of print]
52. C.J. Van der Schyf, W.J. Geldenhuys, and M.B. Youdim Multifunctional drugs with different CNS targets for neuropsychiatric disorders J. Neurochem. 99 2006 1033 1048
53. O. Weinreb, S. Mandel, O. Bar-Am, and T. Amit Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim J. Neural Transm. 118 2011 479 492
54. G.F. Xavier, F.J. Oliveira-Filho, and A.M. Santos Dentate gyrus-selective colchicine lesion and disruption of performance in spatial tasks: difficulties in "place strategy" because of a lack of flexibility in the use of environmental cues? Hippocampus 9 1999 668 681
55. W. Yang, J. Ma, Z. Liu, Y. Lu, B. Hu, and H. Yu Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats Neurol. Sci. 35 2014 741 751
56. M.B. Youdim, D. Ben-Shachar, and S. Yehuda Putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior Am. J. Clin. Nutr. 50 1989 607 615
57. M.B. Youdim, and J.J. Buccafusco Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders Trends Pharmacol. Sci. 26 2005 27 35
58. K.R. Zahs, and K.H. Ashe Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci. 33 2010 381 389
59. H. Zheng, L.M. Weiner, O. Bar-Am, S. Epsztejn, Z.I. Cabantchik, A. Warshawsky, M.B. Youdim, and M. Fridkin Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases Bioorg. Med. Chem. 13 2005 773 783